ATP12A: Key Regulator of TGF-β Pathway (G479)

Target Name: ATP12A

NCBI ID: G479

ATP12A

ATP12A: Key Regulator of TGF-β Pathway

ATP12A, also known as ATP12A_HUMAN, is a protein that is expressed in various tissues of the human body. It is a key regulator of the cell signaling pathway known as the TGF-β pathway, which plays a crucial role in cell growth, differentiation, and repair. The TGF-β pathway is a complex network of proteins that work together to regulate cell behavior, including cell proliferation, migration, and invasion.

ATP12A is a key component of the TGF-β pathway, as it functions as a negative regulator of the pathway. This means that when TGF-β signaling is active, ATP12A works to inhibit the activity of the pathway. Specifically, ATP12A is known to interact with the protein SMAD, which is a negative regulator of the TGF-β pathway. By interacting with SMAD, ATP12A helps to prevent the activity of SMAD, which in turn allows TGF-β signaling to proceed.

ATP12A is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. The TGF-β pathway plays a role in cell adhesion by regulating the activity of the protein cadherin. ATP12A is known to interact with cadherin, and it is thought to help to regulate the activity of cadherin.

In addition to its role in cell signaling and adhesion, ATP12A is also involved in the regulation of cell cycle progression. The TGF-β pathway is involved in regulating the cell cycle, and ATP12A is known to play a role in this process. Specifically, ATP12A is involved in the regulation of the G1 phase of the cell cycle, which is the phase of cell growth and preparation for cell division.

ATP12A is also involved in the regulation of cell survival. The TGF-β pathway is involved in regulating cell survival, and ATP12A is known to play a role in this process. Specifically, ATP12A is involved in the regulation of cell survival by preventing the activity of the protein p53, which is a negative regulator of the TGF-β pathway. By interacting with p53, ATP12A helps to prevent the activity of p53, which in turn allows TGF-β signaling to proceed.

ATP12A is also involved in the regulation of cell signaling in the context of cancer. The TGF-β pathway is known to be involved in the development and progression of cancer, and ATP12A is thought to play a role in this process. For example, it is known that ATP12A is involved in the regulation of cell proliferation in cancer cells. In addition, ATP12A is also involved in the regulation of cell migration and invasion in cancer, which are processes that are critical for tumor growth and metastasis.

In conclusion, ATP12A is a protein that is involved in various aspects of cell signaling and cell behavior, including cell growth, differentiation, repair, adhesion, and survival. It is a key regulator of the TGF-β pathway and is involved in the regulation of cell cycle progression, cell survival, and cell signaling in the context of cancer. As a result, ATP12A is a potential drug target and biomarker for a variety of diseases, including cancer.

Protein Name: ATPase H+/K+ Transporting Non-gastric Alpha2 Subunit

Functions: The catalytic subunit of a H(+)/K(+) ATPase and/or Na(+)/K(+) ATPase pump which transports K(+) ions in exchange for Na(+) and/or H(+) ions across the apical membrane of epithelial cells. Uses ATP as an energy source to pump K(+) ions into the cell while transporting Na(+) and/or H(+) ions to the extracellular compartment (PubMed:9774385, PubMed:7485470, PubMed:8853415, PubMed:11341842). Involved in the maintenance of electrolyte homeostasis through K(+) ion absorption in kidney and colon (By similarity). In the airway epithelium, may play a primary role in mucus acidification regulating its viscosity and clearance (PubMed:29391451)

The "ATP12A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP12A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets